EPIX News and Press, ESSA Pharma Inc. From 02/13/24

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023 Canada NewsWire Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation i...

ESSA Pharma Inc. (EPIX) is expected to report $-0.17 for Q1 2024 QuidelOrtho Corp Com (QDEL) is expected to report $2.01 for Q4 2023 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 Portsmouth Square, Inc. (PRSI) is expected to report for Q2 2024 Similarweb Ltd. (SMWB) ...

ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference Canada NewsWire SOUTH SAN FRANCISCO , California and VANCOUVER, Canada , Feb. 6, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), ...

Algoma Steel Group Inc. (ASTL) is expected to report for Q3 2024 CTS Corporation (CTS) is expected to report for Q4 2023 Xylem Inc. New (XYL) is expected to report $0.96 for Q4 2023 TIM S.A. American Depositary Shares (Each representing 5) (TIMB) is expected to report for Q4 2023 ...

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium Canada NewsWire Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC...

2024-01-12 10:00:21 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Health stocks to watch this earnings season as sector poised for resurgence Seeking Al...

2023-12-30 09:05:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-12 12:03:23 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips ESSA Pharma (NASDAQ: EPIX ) just reported results for the fourth quarter of 2023. ESSA Pharma reported earnings per share of -12 cents. This was above the analyst estimate...

2023-12-12 07:25:31 ET More on ESSA Pharma ESSA Pharma: Unique N-Terminal Domain Approach Might Hinder mCRPC Resistance Seeking Alpha’s Quant Rating on ESSA Pharma Historical earnings data for ESSA Pharma Financial information for ESSA Pharma F...

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023 Canada NewsWire Phase 1 dose escalation complete for masofaniten (EPI-7386)/enzalutamide combination study in patients with mCRPC; compelling safety ...